Cinctive Capital Management LP Sells 53,923 Shares of Sanofi $SNY

Key Points

• Cinctive Capital Management LP reduced its stake in Sanofi by 49.8%, now holding 54,394 shares valued at $3,017,000, according to a recent SEC filing.
• Sanofi's stock is currently priced at $45.33, showing a 9.1% decline recently, with analysts anticipating an earnings per share of 4.36 for the fiscal year.
• Recent analyst ratings for Sanofi include a buy rating from Guggenheim and upgrades from JPMorgan and Wall Street Zen, with a target price set at $62.00.

Cinctive Capital Management LP lowered its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 49.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,394 shares of the company's stock after selling 53,923 shares during the quarter. Cinctive Capital Management LP's holdings in Sanofi were worth $3,017,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its position in Sanofi by 124.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock worth $1,344,000 after purchasing an additional 13,358 shares in the last quarter. Axxcess Wealth Management LLC grew its holdings in shares of Sanofi by 130.5% in the first quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock valued at $568,000 after acquiring an additional 5,794 shares in the last quarter. Ballentine Partners LLC grew its holdings in shares of Sanofi by 68.7% in the first quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock valued at $1,445,000 after acquiring an additional 10,617 shares in the last quarter. Sowell Financial Services LLC bought a new position in shares of Sanofi in the first quarter valued at approximately $328,000. Finally, Farther Finance Advisors LLC grew its holdings in shares of Sanofi by 66.2% in the first quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock valued at $338,000 after acquiring an additional 2,476 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Price Performance

NASDAQ SNY traded up $1.17 during trading hours on Friday, hitting $46.50. The company had a trading volume of 7,259,330 shares, compared to its average volume of 2,563,254. The firm has a 50 day simple moving average of $48.81 and a 200 day simple moving average of $51.36. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. Sanofi has a 52 week low of $44.73 and a 52 week high of $60.12. The firm has a market capitalization of $114.18 billion, a price-to-earnings ratio of 11.18, a PEG ratio of 1.10 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter last year, the business posted $1.73 earnings per share. Sanofi's revenue was down 7.0% compared to the same quarter last year. Equities research analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of recent analyst reports. Morgan Stanley set a $56.00 price objective on Sanofi in a research note on Monday, June 2nd. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. JPMorgan Chase & Co. raised Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft raised Sanofi from a "hold" rating to a "buy" rating in a report on Tuesday, September 2nd. Finally, Guggenheim reiterated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Three research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Sanofi presently has a consensus rating of "Buy" and an average target price of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.